Sanofi, Warp Drive Bio to Collaborate on Development of Novel Oncology Therapies and Antibiotics Based on Proprietary Platforms

Sanofi

and Warp Drive Bio, a privately held biotechnology company using the molecules and mechanisms of nature to discover and develop transformative medicines, today announced that they have extended and reshaped their existing collaboration utilizing Warp Drive's proprietary SMART™ (Small Molecule Assisted Receptor Targeting) and Genome Mining platforms to discover novel oncology therapeutics and antibiotics. Sanofi, who has been a major investor and strategic partner since Warp Drive's inception in 2012, and Warp Drive have entered into a research collaboration and exclusive license focused on the development of drugs targeting important human oncogenes including RAS, which has one of the highest mutation rates in cancer and new antibiotics targeting